Editor’s note: This is a developing news story. Please check back soon for updates.
A phase 3 clinical trial investigating ST-100 for the treatment of dry eye disease did not meet its primary endpoint but demonstrated fast-acting healing of the ocular surface, according to a press release from Stuart Therapeutics.
The randomized, double-masked, vehicle-controlled trial investigated ST-100 (vezocolmitide), a collagen mimetic peptide, over 29 days, with the primary endpoint being “a significant increase in the proportion of patients exhibiting a greater than 10 mm improvement from